Adoption of mobile and connected health tech in clinical trials is a real-world challenge for pharmaceutical companies. Our CEO Pierre-Alexandre Fournier has shared his thoughts recently about the adoption of mobile and connected health tech with Fierce Pharma.
"The industry needs to get with it now or pay for it later—literally. The reason? Sensor tech will be adopted faster at a large scale in healthcare than in pharma trials, and that means “the drugs you are developing today are going to be seen with tools that you are not using in your trials right now.” That could cost drugmakers billions of dollars if they launch products only to find that monitoring tech turns up real-world outcomes that don’t meet payers’ standards."
Read more on Fierce Pharma.